Drug detailing in academic medical centers: regulating for the right reasons, with the right evidence, at the right time.
作者信息
Steinman Michael A, Schillinger Dean
机构信息
University of California, San Francisco, CA, USA.
出版信息
Am J Bioeth. 2010 Jan;10(1):21-3. doi: 10.1080/15265160903441103.
Abstract
摘要
相似文献
1
Drug detailing in academic medical centers: regulating for the right reasons, with the right evidence, at the right time.
Am J Bioeth. 2010 Jan;10(1):21-3. doi: 10.1080/15265160903441103.
2
The details are in the field.
Am J Bioeth. 2010 Jan;10(1):19-21. doi: 10.1080/15265160903460921.
3
Avoiding over-deterrence in managing physicians' relationships with industry.
Am J Bioeth. 2010 Jan;10(1):27-9. doi: 10.1080/15265160903441129.
4
Drug detailers, professionalism, and prudence.
Am J Bioeth. 2010 Jan;10(1):9-10. doi: 10.1080/15265160903441020.
5
Contact with pharmaceutical representatives: where does prudence lead?
Am J Bioeth. 2010 Jan;10(1):11-3. doi: 10.1080/15265160903441046.
6
The AAMC exhibits the behavior it condemns.
Am J Bioeth. 2010 Jan;10(1):26-7. doi: 10.1080/15265160903441095.
7
The devil in the detail(ing).
Am J Bioeth. 2010 Jan;10(1):15-7. doi: 10.1080/15265160903460905.
8
Why academic medical centers should ban drug company gifts to individuals.
Am J Bioeth. 2010 Jan;10(1):13-5. doi: 10.1080/15265160903441061.
9
The pitfalls of misreading: what does "industry funding of medical education" actually say?
Am J Bioeth. 2010 Jan;10(1):24-5. doi: 10.1080/15265160903441038.
10
Response to open peer commentaries on "The pitfalls of deducing ethics from economics: why the Association of American Medical Colleges is wrong about pharmaceutical detailing".
Am J Bioeth. 2010 Jan;10(1):W1-3. doi: 10.1080/15265160903493088.
本文引用的文献
1
Following the script: how drug reps make friends and influence doctors.
PLoS Med. 2007 Apr;4(4):e150. doi: 10.1371/journal.pmed.0040150.
2
Narrative review: the promotion of gabapentin: an analysis of internal industry documents.
Ann Intern Med. 2006 Aug 15;145(4):284-93. doi: 10.7326/0003-4819-145-4-200608150-00008.
3
The effects and role of direct-to-physician marketing in the pharmaceutical industry: an integrative review.
Yale J Health Policy Law Ethics. 2005 Summer;5(2):785-822.
4
Interactions between pharmaceutical representatives and doctors in training. A thematic review.
J Gen Intern Med. 2005 Aug;20(8):777-86. doi: 10.1111/j.1525-1497.2005.0134.x.
5
Synergy between publication and promotion: comparing adoption of new evidence in Canada and the United States.
Am J Med. 2003 Oct 15;115(6):467-72. doi: 10.1016/s0002-9343(03)00422-4.
6
Medical professionalism--focusing on the real issues.
N Engl J Med. 2000 Apr 27;342(17):1284-6. doi: 10.1056/NEJM200004273421711.
7
Physicians and the pharmaceutical industry: is a gift ever just a gift?
JAMA. 2000 Jan 19;283(3):373-80. doi: 10.1001/jama.283.3.373.
Zotero 插件